Impact of Genetic Variant Reassessment on the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy Based on the 2010 Task Force Criteria.

Background - Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy, which is associated with life-threatening ventricular arrhythmias. Approximately 60% of patients carry a putative disease-causing genetic variant, but interpretation of genetic test results can be challenging. The aims of this study were to systematically reclassify genetic variants in patients with ARVC and to assess the impact on ARVC diagnosis. Methods - This study included patients from the Multicenter Zurich ARVC Registry who hosted a genetic variant deemed to be associated with the disease. Reclassification of pathogenicity was performed according to the modified 2015 American College of Medical Genetics (ACMG) criteria. ARVC diagnosis (categories: definite, borderline, possible) based on the 2010 Task Force Criteria (TFC) was reclassified after genetic re-adjudication. Results - In 79 patients bearing 80 unique genetic variants, n=47 (58.8%) genetic variants were reclassified, and reclassification was judged to be clinically relevant in n=33 (41.3%). Variants in plakophilin-2 (PKP2) were shown to reclassify less frequently as compared to other genes (PKP2, n=1, 8.3%; desmosomal non-PKP2, n=20, 66.7%; non-desmosomal, n=26, 68.4%) (p=0.001 for overall comparison; PKP2 vs desmosomal non-PKP2, p=0.001; PKP2 vs non-desmosomal, p< 0.001). Genetic reclassification impacted ARVC diagnosis. Eight patients (10.1%) were downgraded from definite to borderline/possible disease at the time of initial genetic testing as well as last follow-up, respectively. Separate genetic reclassification in family members led to downgrading of n=5 (38.5%) of variants. Conclusions - Given that approximately half of genetic variants were reclassified, with 10.1% of patients losing their definite disease status, accurate determination of variant pathogenicity is of utmost importance in the diagnosis of ARVC.

[1]  F. Ruschitzka,et al.  Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. , 2020, American heart journal.

[2]  M. Link,et al.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. , 2019, Heart rhythm.

[3]  Brandon K. Fornwalt,et al.  Prevalence and Electronic Health Record-based Phenotype of Loss-of-function Genetic Variants in Arrhythmogenic Right Ventricular Cardiomyopathy-associated Genes. , 2019, Circulation. Genomic and precision medicine.

[4]  H. Calkins,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo: Segregation and Haplotype Analysis of a Multinational Cohort. , 2019, Circulation. Genomic and precision medicine.

[5]  Shengshou Hu,et al.  A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression. , 2019, European heart journal.

[6]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[7]  R. Frank,et al.  Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.

[8]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[9]  W. Berger,et al.  Arrhythmogenic right ventricular cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  J. Skinner,et al.  Inpatient detection of cardiac-inherited disease: the impact of improving family history taking , 2016, Open Heart.

[11]  L. Brooks,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[12]  Stefan L. Zimmerman,et al.  Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members , 2015, Circulation. Cardiovascular genetics.

[13]  M. Swertz,et al.  The ARVD/C Genetic Variants Database: 2014 Update , 2015, Human mutation.

[14]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[15]  Stefan L. Zimmerman,et al.  Yield of serial evaluation in at-risk family members of patients with ARVD/C. , 2014, Journal of the American College of Cardiology.

[16]  H. Calkins,et al.  Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Cardiac Sarcoidosis: Distinguishing Features When the Diagnosis Is Unclear , 2014, Circulation. Arrhythmia and electrophysiology.

[17]  C. Semsarian,et al.  Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment , 2013, Genetics in Medicine.

[18]  J. Towbin,et al.  Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. , 2013, Journal of the American College of Cardiology.

[19]  Y. Oade,et al.  Arrhythmogenic right ventricular cardiomyopathy , 2011, BMJ Case Reports.

[20]  R. Hauer,et al.  Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. , 2011, Journal of the American College of Cardiology.

[21]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[22]  John C Chambers,et al.  Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. , 2010, Annual review of medicine.

[23]  F. Crea,et al.  High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy. , 2009, Journal of the American College of Cardiology.

[24]  Dudley J Pennell,et al.  Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. , 2008, Journal of the American College of Cardiology.

[25]  R. Hauer,et al.  Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2006, Circulation.

[26]  M. Simpson,et al.  Novel Mutation in Desmoplakin Causes Arrhythmogenic Left Ventricular Cardiomyopathy , 2005, Circulation.

[27]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[28]  [The European Society of Human Genetics]. , 1967, Annales de Genetique.